Want to see BCAB full AI Analyst Report?
Top Page
BioAtla
(NASDAQ:BCAB)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.00
▲(2005.26% Upside)
Action:Reiterated
Date:07/08/26
The score is primarily held back by weak financial performance—minimal revenue, substantial ongoing losses, persistent cash burn, and negative equity that raises balance-sheet risk. Technical indicators provide only modest near-term support, while valuation signals are limited because the company is unprofitable and has no dividend yield data.
Positive Factors
Proprietary CAB platform and focused oncology pipeline
BioAtla's CAB platform is a durable competitive asset: tumor‑selective activation can materially improve therapeutic index versus conventional antibodies. A focused solid‑tumor pipeline built on that platform supports differentiated clinical value, licensing appeal and long‑term strategic optionality if clinical outcomes validate the approach.
Negative Factors
Minimal and declining revenue base
A tiny, volatile revenue base undermines predictability and scale: with only $2.0M TTM revenue after a steep decline, fixed R&D and G&A costs are unlikely to be absorbed internally. This increases dependence on external financing or partner payments, and makes operating leverage and long‑term planning fragile.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary CAB platform and focused oncology pipeline
BioAtla's CAB platform is a durable competitive asset: tumor‑selective activation can materially improve therapeutic index versus conventional antibodies. A focused solid‑tumor pipeline built on that platform supports differentiated clinical value, licensing appeal and long‑term strategic optionality if clinical outcomes validate the approach.
Read all positive factors
BioAtla (BCAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.60M
Dividend YieldN/A
Average Volume (3M)51.62K
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue Growth-81.82%
EPS Growth31.28%
CountryUS
Employees61
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-41.72
Shares Outstanding1,659,554
10 Day Avg. Volume64,558
30 Day Avg. Volume51,620
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit4.06
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
BioAtla Business Overview & Revenue Model
Company Description
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeu...
How the Company Makes Money
BioAtla is a clinical-stage biotechnology company and, as such, it generally does not rely on recurring product sales; instead, its revenue model is primarily driven by collaboration- and partnership-related income and other R&D-linked payments wh...
BioAtla Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials, strategic transactions, and market potential for BioAtla's programs, with robust data supporting their CAB platform's potential. However, financial challenges were noted, including increased net loss and decreased cash reserves.Positive Updates
FDA Alignment on Phase Three Trial Design
BioAtla achieved FDA alignment on the phase three OSV registrational trial design for OPSCC, which includes a dual primary endpoints design for potential accelerated approval followed by full approval.
Negative Updates
Increased Net Loss
Reported a net loss of $15.8 million for the third quarter of 2025, compared to a net loss of $10.6 million in the same quarter of 2024, primarily due to collaboration revenue recorded in 2024 and a non-cash loss on warrant liability in 2025.
Read all updates
Q3-2025 Updates
Positive
Negative
FDA Alignment on Phase Three Trial Design
BioAtla achieved FDA alignment on the phase three OSV registrational trial design for OPSCC, which includes a dual primary endpoints design for potential accelerated approval followed by full approval.
Read all positive updates
Company Guidance
During BioAtla, Inc.'s third quarter 2025 earnings call, the company provided several key metrics and updates. They are in advanced stages of finalizing a strategic transaction with a potential partner by year-end. The FDA has aligned with their phase three OSV registrational trial design for second-line plus oropharyngeal squamous cell carcinoma (OPSCC), targeting dual primary endpoints of overall response rate and overall survival, with potential for accelerated approval. The estimated worldwide peak sales for their OSFI product in second-line OPSCC alone are approximately $800 million, with the total OPSCC market projected to reach $3 billion by 2032. They reported a net loss of $15.8 million for the quarter, an increase from a $10.6 million net loss in the same quarter of 2024. BioAtla, Inc. had $8.3 million in cash and cash equivalents as of September 30, 2025, and expects R&D expenses to decline as they concentrate resources on prioritized programs.BioAtla Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.00M | 2.00M | 11.00M | 0.00 | 0.00 | 250.00K |
| Gross Profit | 2.12M | 2.00M | 10.07M | -1.22M | -1.20M | -58.02M |
| EBITDA | -47.79M | -59.23M | -68.85M | -122.24M | -105.28M | -94.07M |
| Net Income | -50.62M | -59.61M | -69.78M | -123.46M | -105.28M | -95.40M |
Balance Sheet | ||||||
| Total Assets | 8.57M | 13.83M | 52.42M | 119.66M | 225.74M | 254.42M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 7.12M | 49.05M | 111.47M | 215.51M | 244.98M |
| Total Debt | 6.09M | 6.20M | 836.00K | 2.46M | 3.98M | 5.37M |
| Total Liabilities | 45.88M | 50.02M | 38.16M | 48.99M | 45.40M | 43.60M |
| Stockholders Equity | -37.31M | -36.19M | 14.27M | 70.67M | 180.34M | 210.82M |
Cash Flow | ||||||
| Free Cash Flow | -37.18M | -48.20M | -71.94M | -104.11M | -90.69M | -63.14M |
| Operating Cash Flow | -37.18M | -48.20M | -71.94M | -104.02M | -90.42M | -62.21M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -98.00K | -265.00K | -924.00K |
| Financing Cash Flow | 6.78M | 6.28M | 9.51M | 77.00K | 61.21M | 69.51M |
BioAtla Technical Analysis
Neutral
0.19
Price Trends
3.96
Positive
5.74
Negative
18.96
Negative
Market Momentum
0.06
Negative
52.89
Neutral
74.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCAB, the sentiment is Neutral. The current price of 0.19 is below the 20-day moving average (MA) of 3.76, below the 50-day MA of 3.96, and below the 200-day MA of 18.96, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 52.89 is Neutral, neither overbought nor oversold. The STOCH value of 74.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BCAB.
BioAtla Risk Analysis
BioAtla disclosed 91 risk factors in its most recent earnings report. BioAtla reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioAtla Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $50.14M | -2.46 | -0.97% | ― | ― | 21.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $432.85M | -1.85 | -53.23% | ― | -100.00% | -290.26% | |
46 Neutral | $7.60M | -0.10 | 166.67% | ― | -81.82% | 31.28% | |
42 Neutral | $30.15M | -1.40 | -218.67% | ― | ― | 48.96% | |
| ― | $88.77M | -2.15 | -284.80% | ― | ― | 16.55% |
* Healthcare Sector Average
BCAB
BioAtla
4.08
-15.33
-78.97%
ATNM
Actinium Pharmaceuticals
1.05
-0.38
-26.57%
LTRN
Lantern Pharma
3.57
0.03
0.85%
IPSC
Century Therapeutics
2.31
1.75
311.03%
MAIA
MAIA Biotechnology, Inc.
1.47
-0.37
-20.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.